ElexoPharm GmbH Receives EuroTransBio (ETB) Grant for Tumor Vessel Targeting Program (‘Small Mol Act’)

ETB_Logo ElexoPharm_Logo

Saarbrücken, Germany, October 17,  2012 / B3C newswire / - Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program. The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany). This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer. At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.

"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.

About Elexopharm
ElexoPharm GmbH is a German biotech company located in Saarbrücken, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University headed by Professor Rolf Hartmann. ElexoPharm is focused on the preclinical discovery and optimization of novel innovative drugs for human diseases, which are currently not or insufficiently treatable with existing drugs. One of the largest success of ElexoPharm was the execution of an exclusive license and collaboration agreement with Merck & Co. Inc. for one of its own research projects (development of aldosterone synthase inhibitors for the treatment of cardiovascular diseases) in 2010.

Axel Koch, MBA
Managing Director
ElexoPharm GmbH
Im Stadtwald, A1.1
66123 Saarbrücken
Phone: +49 (0) 681 - 302 68320
Fax: +49 (0) 681 - 910 2894
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.